Skip to main navigation
Skip to search
Skip to main content
Albert Einstein College of Medicine Home
Search content at Albert Einstein College of Medicine
Home
Faculty
Departments
Grants
Publications
Prizes
Overcoming immune resistance in prostate cancer: Challenges and advances
Miyad Movassaghi
, Rainjade Chung
, Christopher B. Anderson
, Mark Stein
,
Yvonne Saenger
, Izak Faiena
Research output
:
Contribution to journal
›
Review article
›
peer-review
25
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Overcoming immune resistance in prostate cancer: Challenges and advances'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Prostate Cancer
100%
Immune Resistance
100%
Treatment Modalities
66%
Cellular Immunity
66%
Advanced Prostate Cancer
66%
Immunosuppressive Microenvironment
66%
Immune Response
33%
Treatment Efficacy
33%
Immune System
33%
Radiotherapy
33%
Chemotherapy
33%
Specific Mechanisms
33%
Prostate Tumor
33%
Clinical Response
33%
Ongoing Trials
33%
Tumor-specific
33%
Chemotherapy Resistance
33%
Lethality
33%
Antibody-drug Conjugate
33%
Advanced Cancer
33%
Durable Response
33%
Cancer-specific
33%
Immunotherapeutic Strategy
33%
Hormonal Therapy
33%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
33%
Multiple Strategies
33%
Checkpoint Inhibitors
33%
Immunosuppressive Cells
33%
Tumor mutational Burden
33%
Chimeric Antigen Receptor T-cell Therapy
33%
Medicine and Dentistry
Prostate Cancer
100%
Immunity
100%
Immunotherapy
66%
Tumor Microenvironment
33%
Cellular Immunity
33%
Immunosuppressive Drug
33%
Neoplasm
16%
Combination Therapy
16%
Immune System
16%
Radiation Therapy
16%
Hormone Therapy
16%
Immunoglobulin
16%
Specific Tumor
16%
Immune Response
16%
Advanced Cancer
16%
Prostate Tumor
16%
Lethality
16%
Chimeric Antigen Receptor T-Cell Immunotherapy
16%
Immunology and Microbiology
Immunotherapy
100%
Immunity
100%
Prostate
75%
Adoptive Immunity
50%
Immunosuppressive Drug
50%
Immune Response
25%
Immune System
25%
Intravenous Immunoglobulin
25%
Vaccine Efficacy
25%
Chimeric Antigen Receptor T-Cell Therapy
25%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Immunotherapy
66%
Tumor Microenvironment
33%
Immunosuppressive Agent
33%
Neoplasm
16%
Chemotherapy
16%
Combination Therapy
16%
Prostate Tumor
16%
Immunoglobulin
16%
Advanced Cancer
16%
Lethality
16%
Hormone Cancer Therapy
16%
Chimeric Antigen Receptor
16%